EGFR and breast carcinoma: Although therapeutic agents such as Herceptin, which are designed to inhibit ERBB activity, have dramatically improved the survival of patients with HER2 positive breast cancer, approximately 50% of patients acquire drug resistance within 1 year (Zahnow, 2006).